1. Home
  2. MPB vs OMER Comparison

MPB vs OMER Comparison

Compare MPB & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mid Penn Bancorp

MPB

Mid Penn Bancorp

HOLD

Current Price

$31.77

Market Cap

856.0M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$14.73

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPB
OMER
Founded
1868
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
856.0M
772.8M
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
MPB
OMER
Price
$31.77
$14.73
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$37.00
$32.50
AVG Volume (30 Days)
110.0K
983.1K
Earning Date
04-21-2026
05-14-2026
Dividend Yield
2.66%
N/A
EPS Growth
N/A
98.15
EPS
0.36
N/A
Revenue
N/A
$29,868,000.00
Revenue This Year
$30.95
N/A
Revenue Next Year
$9.45
$233.22
P/E Ratio
$89.53
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.83
$2.95
52 Week High
$35.22
$17.65

Technical Indicators

Market Signals
Indicator
MPB
OMER
Relative Strength Index (RSI) 39.73 64.28
Support Level $31.17 $10.82
Resistance Level $31.95 $15.32
Average True Range (ATR) 0.86 0.64
MACD -0.23 -0.07
Stochastic Oscillator 13.74 73.59

Price Performance

Historical Comparison
MPB
OMER

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: